Seminars in Nephrology
Volume 29, Issue 6 , Pages 636-642 , November 2009

Renal Osteodystrophy and Aging

  • Donald J. Sherrard, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Donald J. Sherrard, MD, VA Medical Center and the University of Washington, Seattle, WA 98108

References 

  1. Sherrard DJ. Aluminum—much ado about something. N Engl J Med. 1991;324:558–559
  2. Johnson C, Graham B, Kings F, Curtis B. Roentgenographic manifestations of chronic renal disease treated by intermittent hemodialysis. AJR Am J Roentgenol. 1967;101:915–926
  3. Sherrard DJ. Renal osteodystrophy. Semin Nephrol. 1986;6:56–67
  4. Brickman AS, Sherrard DJ, Jowsey J, et al. 1,25 dihydrocholecalciferol in uremic osteodystrophy. Arch Intern Med. 1974;134:883–888
  5. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Kidney Int. 1998;53:223–227
  6. Sherrard DJ. Calcimimetics in action. Kidney Int. 1998;53:510–511
  7. Melton AL. Hip fractures in the elderly: a world wide projection. Osteoporosis Int. 1983;2:285–293
  8. Alem A, Sherrard DJ, Gillen DL, et al. Increased risk of hip fractures among patients with end stage renal disease. Kidney Int. 2000;58:396–399
  9. Stehman-Breen C, Sherrard DJ, Alem A, et al. Risk factors of hip fracture among patents with endstage renal disease. Kidney Int. 2000;58:2200–2205
  10. The Physicians Desk Reference. Fosamax. 2006;60:1949–1956
  11. Boutsen Y, Jamart J, Eiselinckx JP. Primary prevention of glucocorticoid-induced osteoporosis with intravenous calcium and pamidronate. J Bone Miner Res. 2001;16:104–112
  12. Shane E. Osteoporosis associated with illness and medications. In:  Marcus R,  Feldman D,  Kelsey J editor. Osteoporosis. San Diego: Academic Press; 1996;p. 925–946
  13. Melton LJ, Leibson CT, Aschenbach SJ, et al. Fracture risk in type 2 diabetes: update of a population based study. J Bone Miner Res. 2008;23:1334–1342
  14. Turner CH, Robling AG. Exercise as an anabolic stimulus to bone. Curr Pharm Des. 1998;10:2629–2641
  15. Arnaud SB, Sherrard DJ, Maloney N, et al. Effects of one week head down tilt bed rest on bone formation and the calcium endocrine system. Aviat Space Environ Med. 1992;63:14–20
  16. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266–279
  17. Miller PD, Roux C, Brown S, et al. Safety and efficacy of risedronate in patients with age related renal function impairment as estimated by the Cockcroft and Gault method (A pooled analysis of nine clinical trials). J Bone Miner Res. 2005;12:2105–2115
  18. Toussaint NG, Elder GJ, Kerr PC. Bisphosphonates in chronic kidney disease; balancing potential benefits and adverse effects on bone and soft tissue. Clin J Am Soc Nephrol. 2009;4:221–233
  19. Woo SB, Hellstein JW, Kalmer JR. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–761
  20. Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74:1385–1393
  21. Black DM. Effects of continuing or stopping Alendronate after 5 years of treatment. JAMA. 2006;296:2927–2938
  22. Ott SM. Long term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90:1897–1899

 Honorarium received from Zymogenetics (Seattle, WA). No conflicts of interest exist.

PII: S0270-9295(09)00151-X

doi: 10.1016/j.semnephrol.2009.07.007

Seminars in Nephrology
Volume 29, Issue 6 , Pages 636-642 , November 2009

Article Tools

* Image Usage & Resolution